全体要約
北米はヘルスケア分析試験サービス市場で最大のシェアを持ち、特に米国のバイオ医薬品および製薬会社の急増が要因です。業界の主要プレイヤーには、ユーロフィン・サイエンティフィック、アメリカのラボラトリーコーポレーション、SGS、メドペース、チャールズリバーラボラトリーズなどが含まれます。北米の先進的なインフラや規制環境は、この市場のリーダーシップを支えています。
関連する質問
12.6億ドル（2029年）
11.2%（2024年から2029年）
Eurofins Scientific, Laboratory Corporation of America Holdings, SGS S.A., Medpace Holdings, Inc., LGC Limited, Parexel International Corporation, Celerion, Pharmaron, BioAgilytix Labs, Charles River Laboratories, WuXi AppTec Co. Ltd., Element Materials Technology, Thermo Fisher Scientific, Inc., Pace Analytical Services LLC, Intertek Group plc, IQVIA Inc., Merck KGaA, Source BioScience, Almac Group, ICON Plc, Frontage Laboratories, Inc., STERIS Plc, Sartorius AG, ALS Life Science, Syneos Health, INC
品質保証と規制遵守に対する需要の増加, 医薬品およびバイオ医薬品における分析試験の焦点, 政府の支援立法による投資促進
概要
「バイオヘルスケア分析テストサービスセグメントは、2023年のヘルスケア分析テストサービス市場において、タイプ別で大きなシェアを占めました。」
バイオヘルスケアの分析テストサービスセグメントは、2023年の世界のヘルスケア分析テストサービス市場で37.1%の最大シェアを占めると予測されています。また、予測期間中に10.7%の最高CAGRで成長する見込みです。ヘルスケア分析テストサービス市場は、バイオ分析テスト、物理的特性評価、方法の開発と確認、安定性テスト、バッチリリーステスト、原材料テスト、微生物テスト、ゲノムサービス、環境モニタリングサービスなど、さまざまなカテゴリに分けられています。2023年には、バイオヘルスケアの分析テストサービスセグメントが最大の位置を占めており、これは主にワクチン、小分子、バイオ製剤など異なる薬剤タイプに合わせた包括的な提供によるものです。この広範なサービスの範囲は、製薬およびバイオ製薬会社の多様なニーズを満たすため、セグメントの substantial market share driving へとつながっています。
「細胞ベースのアッセイセグメントは、ヘルスケア分析試験サービス市場で最大のシェアを占めました。」
バイオ分析サービスの種類に基づくと、市場は細胞ベースのアッセイ、ウイルス学的検査、バイオマーカー検査、免疫原性および中和抗体検査、薬物動態検査、その他のバイオヘルスケア分析検査サービスを含みます。2023年には、細胞ベースのアッセイセグメントが市場のリーダーとして表れました。この優位性は、細胞ベースのアッセイが生化学アッセイに比べて関連する in vivo 生物学的洞察を提供するため、高スループットスクリーニングにおける好ましい選択肢となっていることに起因しています。この利点は、薬物発見プロセスを加速し、セグメントの重要性に寄与しています。
「北米は予測期間中に大幅な成長率を目撃するでしょう。」
北米は、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東・アフリカなどの他の地域を上回り、医療分析テストサービス市場で最大のシェアを占めています。この優位性は、主に米国に拠点を置く生物製薬および製薬会社の急増によって推進されています。さらに、米国市場は確立されたプレーヤーの強力な基盤の恩恵を受けており、これが市場の成長軌道をさらに促進しています。この地域の先進的なインフラ、支援的な規制環境、研究開発への重視も、世界の医療分析テストサービス市場におけるリーダーシップの地位に大きく寄与しています。
主要参加者の内訳は、以下の通りです。
• 企業タイプ別 - ティア1：45%、ティア2：30%、ティア3：25%
• 役職別 - C級: 42%、ディレクター級: 31%、その他: 27%
地域別 - 北米: 32%、ヨーロッパ: 32%、アジア太平洋: 26%、その他の地域: 10%
ヘルスケア分析試験サービス市場の主要企業
グローバルなヘルスケア分析試験サービス市場の主要プレーヤーには、ユーロフィン・サイエンティフィック（ルクセンブルク）、アメリカ・ホールディングス社（米国）、SGS S.A.（スイス）、メドペース・ホールディングス（米国）、LGCリミテッド（シンベン）（英国）、パレクセル・インターナショナル（米国）、セレリオン（米国）、ファーマロン（中国）、バイオアジリティクス・ラボ（米国）、チャールズ・リバー・ラボラトリーズ（米国）、ウーシ・アプテック（中国）、エレメント・マテリアル・テクノロジー（英国）、サーモ・フィッシャー・サイエンティフィック（米国）、ペース・アナリティカル・サービス（米国）、インターテック・グループ（英国）、IQVIA（米国）、メルクKGaA（ドイツ）、ソース・バイオサイエンス（英国）、アルマック・グループ（英国）、ICON（アイルランド）、フロンティッジ・ラボラトリーズ（米国）、STERIS（米国）、サルトリウス（ドイツ）、ALSライフサイエンス（米国）、シネオス・ヘルス（米国）が含まれます。
調査範囲：
このレポートは、ヘルスケア分析テストサービス市場を分析し、タイプ、エンドユーザー、および地域に基づいて、さまざまな市場セグメントの市場規模と将来の成長可能性を推定することを目的としています。また、市場で活動している主要なプレーヤーの競争分析、企業プロフィール、製品提供、最近の動向、主要な市場戦略も提供します。
報告書を購入する理由
この報告書は、既存の企業だけでなく、新規参入者や小規模企業が市場の動向を把握するのを支援します。それにより、より大きな市場シェアを獲得する助けとなります。報告書を購入した企業は、以下に述べるいくつかの戦略のいずれか、またはその組み合わせを用いて、市場での地位を強化することができます。
この報告書は以下に関する洞察を提供します：
市場の動向分析（厳しい規制環境、生物学的製品およびバイオシミラーの分析テストに対する関心の高まり、製薬およびバイオファーマR&Dへの投資の増加）、制約（コスト上昇および市場競争による市場プレーヤーへの圧力の増大）、機会（新技術の採用、政府の支援施策）、および課題（バイオ分析手法の感度向上のニーズの増加）
サービス/革新：ヘルスケア分析試験サービス市場における今後の技術、研究開発活動、および新サービスの立ち上げに関する詳細な洞察です。
市場の発展：有望な新興市場、構成要素、人口統計、エンドユーザー、地域に関する包括的な情報。
市場の多様化：製品ポートフォリオ、成長地域、最近の動向、および医療分析試験サービス市場への投資に関する詳細情報
競争評価：ユーロフィン・サイエンティフィック（ルクセンブルク）、アメリカ・ホールディングス（米国）、SGS S.A.（スイス）、チャールズリバー・ラボラトリーズ（米国）、ウーシー・アプテック（中国）、エレメント・マテリアルズ・テクノロジー（英国）などの主要プレーヤーの市場シェア、成長戦略、製品提供、および能力の詳細な評価です。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 イントロダクション 50
1.1 調査の目的 50
1.2 市場の定義 50
1.2.1 包含・除外事項 51
1.2.2 市場セグメンテーション 52
1.2.3 対象地域 53
1.2.4 対象年 53
1.3 通貨 54
1.4 制約 54
1.4.1 手法上の制約 54
1.4.2 範囲上の制約 54
1.5 ステークホルダー 54
1.6 変化のサマリー 55
2 調査手法 56
2.1 リサーチデータ 56
2.2 調査手法デザイン 56
2.2.1 二次調査 57
- 2.2.1.1 二次情報の主要データ 58
2.2.2 一次データ 58
- 2.2.2.1 一次情報の主要データ 60
- 2.2.2.2 一次エキスパート考察 60
2.3 市場規模予測分析の手法 62
2.4 データのトライアンギュレーションプロシージャ 67
2.5 市場シェア推定 68
2.6 調査の前提 68
2.7 リスク評価 68
2.8 リセッション時のインパクト分析 69
3 エグゼクティブサマリー 70
4 更なる考察 75
4.1 ヘルスケア分析試験サービス市場の概要 75
4.2 ヨーロッパ：ヘルスケア分析試験サービス市場：タイプ別、国別（2023年） 76
4.3 ヘルスケア分析試験サービス市場、地理的側面での成長機会 77
4.4 地域的なミックス：ヘルスケア分析試験サービス市場（2022年～2029年） 78
4.5 ヘルスケア分析試験サービス市場：先進国と新興国の比較（2024年と2029年） 79
5 市場概要 80
5.1 イントロダクション 80
5.2 市場ダイナミクス 80
5.2.1 促進要因 81
5.2.2 抑制要因 86
5.2.3 市場機会 87
- 5.2.3.1 新しい技術や技能の採用 87
- 5.2.3.2 新興国経済への関心の高まり 87
5.2.4 課題 88
- 5.2.4.1 スキル人材不足 88
- 5.2.4.2 革新的な製剤および医療機器に対する特定の要件 89
- 5.2.4.3 バイオ分析法の感度向上の必要性 89
5.3 エコシステム分析 90
5.4 バリューチェーン分析 91
5.5 ケーススタディ分析 92
5.5.1 分析試験のアウトソーシングでバイオ医薬品開発の可能性を引き出す 92
5.5.2 医薬品検査に革命を起こす：分析試験進化のケーススタディ 92
5.6 ポーターのファイブフォース分析 92
5.6.1 新規参入の脅威 93
5.6.2 サプライヤーの交渉力 93
5.6.3 競合・競争状況の激しさ 94
5.6.4 買い手の交渉力 94
5.6.5 代替品の脅威 94
5.7 規制の概観 95
5.7.1 規制当局、政府機関、その他組織 95
5.7.2 規制分析 96
5.7.3 北米 98
5.7.4 ヨーロッパ 99
5.7.5 アジア太平洋 100
5.8 顧客事業にインパクトのあるトレンド/ディスラプション 100
5.9 主要なカンファレンスイベント <num4>年～<num4>年 101
5.10 投資と資金調達のシナリオ 102
5.11 主なステークホルダーと購入基準 103
5.11.1 購買プロセスにおける主要ステークホルダー 103
5.11.2 購買基準 104
6 ヘルスケア分析試験サービスの市場、タイプ別 106
6.1 イントロダクション 107
6.2 バイオアナリティカルテスト 107
6.2.1 薬物動態学的および毒物動態学的試験 109
6.2.2 免疫原性および中和抗体試験 110
- 6.2.2.1 市場成長を支える医薬品安全性承認要件の増加 110
6.2.3 バイオマーカーテスト 111
- 6.2.3.1 専門的な医薬品開発ニーズの高まりが市場を牽引 111
6.2.4 バイオアッセイ試験 112
6.2.5 その他バイオ分析試験サービス 113
6.3 物理的特性 114
6.3.1 レーザー粒子サイズ分析 116
6.3.2 熱分析 117
- 6.3.2.1 成長を支える熱分析技術の進歩 117
6.3.3 光学特性評価 117
- 6.3.3.1 成長に寄与する生物学的構造の複雑化 117
6.3.4 表面積分析 118
6.3.5 その他の物理特性測定サービス 119
6.4 メソッド開発・バリデーション 120
6.4.1 抽出物／浸出物 メソッド開発とバリデーション 122
6.4.2 プロセス不純物メソッドの開発とバリデーション 123
- 6.4.2.1 不純物検査重視の高まりが市場を押し上げる 123
6.4.3 安定性指示法のバリデーション 124
6.4.4 洗浄バリデーションとメソッド開発 124
6.4.5 分析標準の特性評価 125
6.4.6 テクニカルコンサルティング 126
- 6.4.6.1 医薬品開発における薬事承認の必要性が市場を牽引 126
6.4.7 その他メソッド開発・バリデーションサービス 127
6.5 原料テスト 128
6.5.1 コンペンディアル・テスト 129
6.5.2 コンテナ・テスト 130
6.5.3 重金属検査 131
6.5.4 水分分析 132
6.5.5 その他原料試験サービス 133
6.6 一括リリーステストサービス 134
6.6.1 溶解試験 135
6.6.2 元素不純物検査 136
6.6.3 崩壊試験 137
6.6.4 硬度試験 139
6.6.5 成形性試験 140
6.6.6 その他のバッチリリーステストサービス 140
6.7 安定性試験 141
6.7.1 薬物安定性試験 142
- 6.7.1.1 医薬品認可のための規制要件が市場を牽引 142
6.7.2 製剤評価 安定性試験 143
6.7.3 加速度安定性試験 144
6.7.4 光安定性試験 145
6.7.5 強制劣化試験 146
6.7.6 その他の安定性試験サービス 147
6.8 微生物検査 148
6.8.1 微生物限度試験 149
6.8.2 ウイルス学的検査 150
- 6.8.2.1 ウイルス性疾患の増加が市場を牽引 150
6.8.3 無菌試験 151
6.8.4 エンドトキシン検査 152
6.8.5 防腐剤の有効性試験 153
6.8.6 その他の微生物検査サービス 154
6.9 ゲノム検査サービス 155
6.10 その他の分析試験サービス 156
7 ヘルスケア分析試験サービスの市場、エンドユーザー別 157
7.1 イントロダクション 158
7.2 製薬会社 158
7.2.1 INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH 158
7.3 バイオ医薬品の会社情報 160
7.3.1 GROWING INVESTMENTS IN BIOPHARMACEUTICAL COMPANIES TO BOOST MARKET GROWTH 160
7.4 医療機器メーカー 161
7.4.1 STRICT APPROVAL NORMS FOR MEDICAL DEVICES TO SUPPORT GROWTH 161
7.5 病院・クリニック 162
7.5.1 慢性疾患の蔓延が市場成長を促す 162
7.6 科学捜査研究所 163
7.7 化粧品・ニュートラシューティカルズ関連企業 164
7.7.1 STRINGENT GUIDELINES FOR QUALITY CONTROL TO DRIVE MARKET 164
8 ヘルスケア分析検査市場、地域別 166
8.1 イントロダクション 167
8.2 北米 168
8.2.1 北米：リセッション時のインパクト 168
8.2.2 米国 175
- 8.2.2.1 パイプラインにある多数の登録前医薬品が市場を牽引 175
8.2.3 カナダ 180
- 8.2.3.1 市場成長を支える老舗CROの存在 180
8.3 ヨーロッパ 185
8.3.1 ヨーロッパ：リセッション時のインパクト 185
8.3.2 ドイツ 191
8.3.3 フランス 196
- 8.3.3.1 有利な政府規制が市場を牽引 196
8.3.4 英国 201
8.3.5 イタリア 205
- 8.3.5.1 市場成長を支える低い医薬品承認期間 205
8.3.6 スイス 210
8.3.7 スペイン 214
- 8.3.7.1 研究開発費の増加が成長を後押し 214
8.3.8 その他のヨーロッパ 219
8.4 アジア太平洋 224
8.4.1 アジア太平洋：リセッション時のインパクト 224
8.4.2 中国 231
- 8.4.2.1 低コストの医薬品が需要を牽引 231
8.4.3 日本 235
- 8.4.3.1 老年人口の増加が市場成長を支える 235
8.4.4 インド 240
- 8.4.4.1 臨床試験の増加が市場を牽引 240
8.4.5 オーストラリア 245
8.4.6 韓国 249
- 8.4.6.1 臨床試験活動の成長が市場を牽引 249
8.4.7 その他のアジア太平洋 254
8.5 ラテンアメリカ 259
8.5.1 ラテンアメリカ：リセッション時のインパクト 259
8.5.2 ブラジル 265
- 8.5.2.1 新興医療技術の採用増加が市場を牽引 265
8.5.3 メキシコ 270
- 8.5.3.1 政府のイニシアティブと堅調な供給が市場を牽引 270
8.5.4 その他のラテンアメリカ 275
8.6 中東・アフリカ 279
8.6.1 中東・アフリカ：リセッション時のインパクト 280
8.6.2 GCC地域 285
- 8.6.2.1 市場成長を支援する政府の取り組み 285
8.6.3 その他の中東・アフリカ 290
9 競合情勢 295
9.1 イントロダクション 295
9.2 主要プレーヤーが採用するRight-to-Winアプローチ 296
9.3 REVENUE SHARE ANALYSIS 297
9.4 市場シェア分析 298
9.5 企業評価マトリックス：主要企業 299
9.5.1 STARS 300
9.5.2 PERVASIVE PLAYERS 300
9.5.3 EMERGING LEADERS 300
9.5.4 PARTICIPANTS 300
9.5.5 企業フットプリント 302
- 9.5.5.1 全体のフットプリント 302
- 9.5.5.2 サービスのフットプリント 303
- 9.5.5.3 エンドユーザーのフットプリント 304
- 9.5.5.4 地域フットプリント 305
9.6 企業評価マトリックス：スタートアップ / 中小企業 306
9.6.1 PROGRESSIVE COMPANIES 306
9.6.2 DYNAMIC COMPANIES 306
9.6.3 RESPONSIVE COMPANIES 306
9.6.4 STARTING BLOCKS 306
9.6.5 競合ベンチマーキング 308
9.7 VALUATION AND FINANCIAL METRICS OF HEALTHCARE ANALYTICAL TESTING SERVICE VENDORS 310
9.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 311
9.8.1 EUROFINS SCIENTIFIC 312
9.8.2 WUXI APPTEC 312
9.8.3 CHARLES RIVER LABORATORIES 312
9.8.4 SGS S.A 312
9.8.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 313
9.9 競合シナリオ 313
9.9.1 サービスローンチ 313
9.9.2 ディール 314
10 企業プロファイル 318
10.1 主要企業 318
10.1.1 EUROFINS SCIENTIFIC 318
10.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS 323
10.1.3 WUXI APPTEC 327
10.1.4 CHARLES RIVER LABORATORIES 332
10.1.5 SGS S.A 338
10.1.6 THERMO FISHER SCIENTIFIC INC 344
10.1.7 MEDPACE, INC 348
10.1.8 SARTORIUS AG 350
10.1.9 INTERTEK GROUP PLC 353
10.1.10 MERCK KGAA 358
10.1.11 SOURCE BIOSCIENCE 363
10.1.12 ICON PLC 366
10.1.13 ALS 369
10.1.14 FRONTAGE LABORATORIES, INC 372
10.1.15 STERIS 377
10.1.16 IQVIA INC 380
10.1.17 ELEMENT MATERIALS TECHNOLOGY 383
10.1.18 PACE ANALYTICAL SERVICES 386
10.1.19 ALMAC GROUP 391
10.1.20 PHARMARON 393
10.2 他の有力企業 395
10.2.1 SYNEOS HEALTH 395
10.2.2 PAREXEL INTERNATIONAL (MA) CORPORATION 396
10.2.3 LGC LIMITED 397
10.2.4 CELERION 398
10.2.5 BIOAGILYTIX 399
11 付録 400
11.1 ディスカッションガイド 400
11.2 ナレッジストア 405
11.3 カスタマイズオプション 407
11.4 関連レポート 407
11.5 執筆者の詳細 408
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
Table of Contents
1 INTRODUCTION 50
1.1 STUDY OBJECTIVES 50
1.2 MARKET DEFINITION 50
1.2.1 INCLUSIONS & EXCLUSIONS 51
1.2.2 MARKET SEGMENTATION 52
1.2.3 REGIONS COVERED 53
1.2.4 YEARS CONSIDERED 53
1.3 CURRENCY CONSIDERED 54
1.4 LIMITATIONS 54
1.4.1 METHODOLOGY-RELATED LIMITATIONS 54
1.4.2 SCOPE-RELATED LIMITATIONS 54
1.5 STAKEHOLDERS 54
1.6 SUMMARY OF CHANGES 55
2 RESEARCH METHODOLOGY 56
2.1 RESEARCH DATA 56
2.2 RESEARCH METHODOLOGY DESIGN 56
2.2.1 SECONDARY RESEARCH 57
- 2.2.1.1 Key data from secondary sources 58
2.2.2 PRIMARY DATA 58
- 2.2.2.1 Key data from primary sources 60
- 2.2.2.2 Insights from primary experts 60
2.3 MARKET SIZE ESTIMATION METHODOLOGY 62
2.4 DATA TRIANGULATION PROCEDURE 67
2.5 MARKET SHARE ESTIMATION 68
2.6 STUDY ASSUMPTIONS 68
2.7 RISK ASSESSMENT 68
2.8 RECESSION IMPACT ANALYSIS 69
3 EXECUTIVE SUMMARY 70
4 PREMIUM INSIGHTS 75
4.1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET OVERVIEW 75
4.2 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE AND COUNTRY (2023) 76
4.3 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 77
4.4 REGIONAL MIX: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2022-2029) 78
4.5 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEVELOPED VS. EMERGING ECONOMIES (2024 VS. 2029) 79
5 MARKET OVERVIEW 80
5.1 INTRODUCTION 80
5.2 MARKET DYNAMICS 80
5.2.1 DRIVERS 81
- 5.2.1.1 Stringent regulatory guidelines 81
- 5.2.1.2 Growing focus on analytical testing of biologics & biosimilars 82
- 5.2.1.3 Increasing outsourcing of analytical testing by pharmaceutical & medical device companies 82
- 5.2.1.4 Increasing number of clinical trials 83
- 5.2.1.5 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry 84
- 5.2.1.6 Rising acceptance of quality-by-design approach in pharmaceutical research & manufacturing 85
5.2.2 RESTRAINTS 86
- 5.2.2.1 Increasing pressure on market players due to rising costs and market competition 86
5.2.3 OPPORTUNITIES 87
- 5.2.3.1 Adoption of new techniques and technologies 87
- 5.2.3.2 Growing focus on emerging economies 87
5.2.4 CHALLENGES 88
- 5.2.4.1 Shortage of skilled professionals 88
- 5.2.4.2 Specific requirements for innovative formulations and medical devices 89
- 5.2.4.3 Need to improve sensitivity of bioanalytical methods 89
5.3 ECOSYSTEM ANALYSIS 90
5.4 VALUE CHAIN ANALYSIS 91
5.5 CASE STUDY ANALYSIS 92
5.5.1 UNLOCKING BIOPHARMACEUTICAL DEVELOPMENT POTENTIAL THROUGH OUTSOURCING ANALYTICAL TESTING 92
5.5.2 REVOLUTIONIZING PHARMACEUTICAL TESTING: A CASE STUDY IN ANALYTICAL TESTING EVOLUTION 92
5.6 PORTER’S FIVE FORCES ANALYSIS 92
5.6.1 THREAT OF NEW ENTRANTS 93
5.6.2 BARGAINING POWER OF SUPPLIERS 93
5.6.3 INTENSITY OF COMPETITIVE RIVALRY 94
5.6.4 BARGAINING POWER OF BUYERS 94
5.6.5 THREAT OF SUBSTITUTES 94
5.7 REGULATORY LANDSCAPE 95
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
5.7.2 REGULATORY ANALYSIS 96
5.7.3 NORTH AMERICA 98
5.7.4 EUROPE 99
5.7.5 ASIA PACIFIC 100
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 100
5.9 KEY CONFERENCES & EVENTS, 2024-2025 101
5.10 INVESTMENT AND FUNDING SCENARIO 102
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 103
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 103
5.11.2 BUYING CRITERIA 104
6 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE 106
6.1 INTRODUCTION 107
6.2 BIOANALYTICAL TESTING 107
6.2.1 PHARMACOKINETIC & TOXICOKINETIC TESTING 109
- 6.2.1.1 Increasing number of clinical trials for drug development to propel growth 109
6.2.2 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING 110
- 6.2.2.1 Increasing requirement for drug safety approvals to support market growth 110
6.2.3 BIOMARKER TESTING 111
- 6.2.3.1 Rising need for specialized drug development to drive market 111
6.2.4 BIOASSAY TESTING 112
- 6.2.4.1 Growing adoption of high-content screening for cytotoxicity testing to fuel growth 112
6.2.5 OTHER BIOANALYTICAL TESTING SERVICES 113
6.3 PHYSICAL CHARACTERIZATION 114
6.3.1 LASER PARTICLE SIZE ANALYSIS 116
- 6.3.1.1 Growing importance of particle size analysis in manufacturing pharmaceutical dosage forms to drive market 116
6.3.2 THERMAL ANALYSIS 117
- 6.3.2.1 Advancements in thermal analysis techniques to support growth 117
6.3.3 OPTICAL CHARACTERIZATION 117
- 6.3.3.1 Growing complexity of biological structures to contribute to growth 117
6.3.4 SURFACE AREA ANALYSIS 118
- 6.3.4.1 Growing need for surface analysis to streamline drug development processes to fuel growth 118
6.3.5 OTHER PHYSICAL CHARACTERIZATION SERVICES 119
6.4 METHOD DEVELOPMENT & VALIDATION 120
6.4.1 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION 122
- 6.4.1.1 Growing development of parenterally administered drugs and biologic products to drive market 122
6.4.2 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION 123
- 6.4.2.1 Rising emphasis on impurity testing to boost market 123
6.4.3 STABILITY-INDICATING METHOD VALIDATION 124
- 6.4.3.1 Need to ensure safety and efficacy of therapeutic drugs to spur growth 124
6.4.4 CLEANING VALIDATION & METHOD DEVELOPMENT 124
- 6.4.4.1 Growing needs to evaluate cleaning practices and ensure complete decontamination to fuel growth 124
6.4.5 ANALYTICAL STANDARD CHARACTERIZATION 125
- 6.4.5.1 Growing importance of analytical standard characterization in drug development to support market 125
6.4.6 TECHNICAL CONSULTING 126
- 6.4.6.1 Need for regulatory approvals for drug development to drive market 126
6.4.7 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES 127
6.5 RAW MATERIAL TESTING 128
6.5.1 COMPLETE COMPENDIAL TESTING 129
- 6.5.1.1 Need to determine efficacy and safety of therapeutic products to drive growth 129
6.5.2 CONTAINER TESTING 130
- 6.5.2.1 Need to optimize sealing and evaluate temperature impact to fuel growth 130
6.5.3 HEAVY METAL TESTING 131
- 6.5.3.1 Implementation of various techniques and technologies for heavy metal testing to aid growth 131
6.5.4 WATER CONTENT ANALYSIS 132
- 6.5.4.1 Need to check for water content in pharmaceutical products to support growth 132
6.5.5 OTHER RAW MATERIAL TESTING SERVICES 133
6.6 BATCH-RELEASE TESTING SERVICES 134
6.6.1 DISSOLUTION TESTING 135
- 6.6.1.1 Wide usage of dissolution testing in formulation development and manufacturing to drive growth 135
6.6.2 ELEMENTAL IMPURITY TESTING 136
- 6.6.2.1 Need to minimize cost of in-house analysis and labor to fuel growth 136
6.6.3 DISINTEGRATION TESTING 137
- 6.6.3.1 Need to ensure batch-to-batch consistency of pharmaceutical dosage forms to promote growth 137
6.6.4 HARDNESS TESTING 139
- 6.6.4.1 Need to assess manufacturability and compactness of pharmaceutical formulations to ensure growth 139
6.6.5 FRIABILITY TESTING 140
- 6.6.5.1 Need to measure resistance of tablets and granules to abrasion or fracture to support market 140
6.6.6 OTHER BATCH-RELEASE TESTING SERVICES 140
6.7 STABILITY TESTING 141
6.7.1 DRUG SUBSTANCE STABILITY TESTING 142
- 6.7.1.1 Regulatory requirements for drug approval to drive market 142
6.7.2 FORMULATION EVALUATION STABILITY TESTING 143
- 6.7.2.1 Need to analyze and predict shelf life of products to drive demand 143
6.7.3 ACCELERATED STABILITY TESTING 144
- 6.7.3.1 Growing use of accelerated stability testing to determine shelf life of pharmaceutical products to fuel growth 144
6.7.4 PHOTOSTABILITY TESTING 145
- 6.7.4.1 Need for robust photostability testing process to ensure product quality and safety to drive adoption 145
6.7.5 FORCED DEGRADATION TESTING 146
- 6.7.5.1 Regulatory requirements and need for comprehensive stability testing in pharmaceutical industry to boost market 146
6.7.6 OTHER STABILITY TESTING SERVICES 147
6.8 MICROBIAL TESTING 148
6.8.1 MICROBIAL LIMIT TESTING 149
- 6.8.1.1 Need to determine whether products comply with compendial specifications for microbial quality to boost adoption 149
6.8.2 VIROLOGY TESTING 150
- 6.8.2.1 Increasing outbreaks of viral diseases to drive market 150
6.8.3 STERILITY TESTING 151
- 6.8.3.1 Rising development of parenteral preparations and immunological products to drive market 151
6.8.4 ENDOTOXIN TESTING 152
- 6.8.4.1 Need to standardize procedures and follow regulatory guidelines to support demand 152
6.8.5 PRESERVATIVE EFFICACY TESTING 153
- 6.8.5.1 Need to ensure product safety for product approval to support growth 153
6.8.6 OTHER MICROBIAL TESTING SERVICES 154
6.9 GENOMIC TESTING SERVICES 155
6.9.1 NEED TO GAIN INSIGHTS INTO DISEASE MECHANISMS AND TREATMENT RESPONSES TO BOOST MARKET 155
6.10 OTHER ANALYTICAL TESTING SERVICES 156
7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER 157
7.1 INTRODUCTION 158
7.2 PHARMACEUTICAL COMPANIES 158
7.2.1 INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH 158
7.3 BIOPHARMACEUTICAL COMPANIES 160
7.3.1 GROWING INVESTMENTS IN BIOPHARMACEUTICAL COMPANIES TO BOOST MARKET GROWTH 160
7.4 MEDICAL DEVICE COMPANIES 161
7.4.1 STRICT APPROVAL NORMS FOR MEDICAL DEVICES TO SUPPORT GROWTH 161
7.5 HOSPITALS & CLINICS 162
7.5.1 GROWING PREVALENCE OF CHRONIC DISEASES TO FAVOR MARKET GROWTH 162
7.6 FORENSIC LABS 163
7.6.1 GROWING USE OF ANALYTICAL TESTING IN FORENSIC LABS TO BOOST MARKET GROWTH 163
7.7 COSMETIC & NUTRACEUTICAL COMPANIES 164
7.7.1 STRINGENT GUIDELINES FOR QUALITY CONTROL TO DRIVE MARKET 164
8 HEALTHCARE ANALYTICAL TESTING MARKET, BY REGION 166
8.1 INTRODUCTION 167
8.2 NORTH AMERICA 168
8.2.1 NORTH AMERICA: RECESSION IMPACT 168
8.2.2 US 175
- 8.2.2.1 High number of pre-registration drugs in pipeline to drive market 175
8.2.3 CANADA 180
- 8.2.3.1 Presence of well-established CROs to support market growth 180
8.3 EUROPE 185
8.3.1 EUROPE: RECESSION IMPACT 185
8.3.2 GERMANY 191
- 8.3.2.1 Government support and flexible labor laws make Germany favorable location for clinical trials 191
8.3.3 FRANCE 196
- 8.3.3.1 Favorable government regulations to drive market 196
8.3.4 UK 201
- 8.3.4.1 Investments by pharmaceutical sponsors for drug discovery services to support growth 201
8.3.5 ITALY 205
- 8.3.5.1 Low drug approval time to support market growth 205
8.3.6 SWITZERLAND 210
- 8.3.6.1 Large and growing pharma production volume to drive demand for analytical testing services 210
8.3.7 SPAIN 214
- 8.3.7.1 Rising R&D expenditure to boost growth 214
8.3.8 REST OF EUROPE 219
8.4 ASIA PACIFIC 224
8.4.1 ASIA PACIFIC: RECESSION IMPACT 224
8.4.2 CHINA 231
- 8.4.2.1 Low manufacturing cost of medicines to drive demand 231
8.4.3 JAPAN 235
- 8.4.3.1 Rising geriatric population to support market growth 235
8.4.4 INDIA 240
- 8.4.4.1 Increasing number of clinical trials to drive market 240
8.4.5 AUSTRALIA 245
- 8.4.5.1 Large number of research institutes make Australia favorable location for drug discovery 245
8.4.6 SOUTH KOREA 249
- 8.4.6.1 Growth in clinical trial activities to propel market 249
8.4.7 REST OF ASIA PACIFIC 254
8.5 LATIN AMERICA 259
8.5.1 LATIN AMERICA: RECESSION IMPACT 259
8.5.2 BRAZIL 265
- 8.5.2.1 Rising adoption of emerging medical technologies to drive market 265
8.5.3 MEXICO 270
- 8.5.3.1 Government initiatives and robust supply to drive market 270
8.5.4 REST OF LATIN AMERICA 275
8.6 MIDDLE EAST & AFRICA 279
8.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 280
8.6.2 GCC 285
- 8.6.2.1 Supportive government initiatives to aid market growth 285
8.6.3 REST OF MIDDLE EAST & AFRICA 290
9 COMPETITIVE LANDSCAPE 295
9.1 INTRODUCTION 295
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 296
9.3 REVENUE SHARE ANALYSIS 297
9.4 MARKET SHARE ANALYSIS 298
9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 299
9.5.1 STARS 300
9.5.2 PERVASIVE PLAYERS 300
9.5.3 EMERGING LEADERS 300
9.5.4 PARTICIPANTS 300
9.5.5 COMPANY FOOTPRINT 302
- 9.5.5.1 Overall footprint 302
- 9.5.5.2 Service footprint 303
- 9.5.5.3 End-user footprint 304
- 9.5.5.4 Regional footprint 305
9.6 COMPANY EVALUATION MATRIX: START-UPS/SMES 306
9.6.1 PROGRESSIVE COMPANIES 306
9.6.2 DYNAMIC COMPANIES 306
9.6.3 RESPONSIVE COMPANIES 306
9.6.4 STARTING BLOCKS 306
9.6.5 COMPETITIVE BENCHMARKING 308
9.7 VALUATION AND FINANCIAL METRICS OF HEALTHCARE ANALYTICAL TESTING SERVICE VENDORS 310
9.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 311
9.8.1 EUROFINS SCIENTIFIC 312
9.8.2 WUXI APPTEC 312
9.8.3 CHARLES RIVER LABORATORIES 312
9.8.4 SGS S.A 312
9.8.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 313
9.9 COMPETITIVE SCENARIO 313
9.9.1 SERVICE LAUNCHES 313
9.9.2 DEALS 314
10 COMPANY PROFILES 318
10.1 KEY PLAYERS 318
10.1.1 EUROFINS SCIENTIFIC 318
10.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS 323
10.1.3 WUXI APPTEC 327
10.1.4 CHARLES RIVER LABORATORIES 332
10.1.5 SGS S.A 338
10.1.6 THERMO FISHER SCIENTIFIC INC 344
10.1.7 MEDPACE, INC 348
10.1.8 SARTORIUS AG 350
10.1.9 INTERTEK GROUP PLC 353
10.1.10 MERCK KGAA 358
10.1.11 SOURCE BIOSCIENCE 363
10.1.12 ICON PLC 366
10.1.13 ALS 369
10.1.14 FRONTAGE LABORATORIES, INC 372
10.1.15 STERIS 377
10.1.16 IQVIA INC 380
10.1.17 ELEMENT MATERIALS TECHNOLOGY 383
10.1.18 PACE ANALYTICAL SERVICES 386
10.1.19 ALMAC GROUP 391
10.1.20 PHARMARON 393
10.2 OTHER PLAYERS 395
10.2.1 SYNEOS HEALTH 395
10.2.2 PAREXEL INTERNATIONAL (MA) CORPORATION 396
10.2.3 LGC LIMITED 397
10.2.4 CELERION 398
10.2.5 BIOAGILYTIX 399
11 APPENDIX 400
11.1 DISCUSSION GUIDE 400
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 405
11.3 CUSTOMIZATION OPTIONS 407
11.4 RELATED REPORTS 407
11.5 AUTHOR DETAILS 408
TABLE 1 RISK ASSESSMENT ANALYSIS TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS TABLE 3 IMPACT ANALYSIS: DRIVERS TABLE 4 IMPACT ANALYSIS: RESTRAINTS TABLE 5 IMPACT ANALYSIS: OPPORTUNITIES TABLE 6 IMPACT ANALYSIS: CHALLENGES TABLE 7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ROLE IN ECOSYSTEM TABLE 8 PORTER’S FIVE FORCES ANALYSIS TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 13 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 14 ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS TABLE 15 OVERVIEW OF GUIDELINES OF LABORATORY SERVICES TABLE 16 DEVELOPMENT OF GLP ACROSS COUNTRIES TABLE 17 REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES TABLE 18 HEALTHCARE ANALYTICAL TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS TABLE 20 KEY BUYING CRITERIA FOR END USERS TABLE 21 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 23 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 24 PHARMACOKINETIC TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 25 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 26 BIOMARKER TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 27 BIOASSAY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 28 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 29 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 30 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 31 LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 32 THERMAL ANALYSIS SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 33 OPTICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 34 SURFACE AREA ANALYSIS SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 35 OTHER PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 36 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 37 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 38 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 39 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 40 STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 41 CLEANING VALIDATION & METHOD DEVELOPMENT SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 42 ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 43 TECHNICAL CONSULTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 44 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 45 RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 46 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 47 COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 48 CONTAINER TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 49 HEAVY METAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 50 WATER CONTENT ANALYSIS SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 51 OTHER RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 52 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 53 BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 54 DISSOLUTION TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 55 ELEMENTAL IMPURITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 56 BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA TABLE 57 DISINTEGRATION TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 58 HARDNESS TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 59 FRIABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 60 OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 61 STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 62 STABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 63 DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 64 FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 65 ACCELERATED STABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 66 PHOTOSTABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 67 FORCED DEGRADATION TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 68 OTHER STABILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 69 MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 70 MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 71 STANDARD LIMITS FOR MICROBIAL LIMIT TESTING TABLE 72 MICROBIAL LIMIT TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 73 VIROLOGY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 74 STERILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 75 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 76 PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 77 OTHER MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 78 GENOMIC TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 79 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 80 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 81 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD MILLION) TABLE 82 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD MILLION) TABLE 83 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022-2029 (USD MILLION) TABLE 84 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION) TABLE 85 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR FORENSIC LABS, BY REGION, 2022-2029 (USD MILLION) TABLE 86 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR COSMETIC & NUTRACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD MILLION) TABLE 87 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 88 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 89 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 90 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 91 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 92 NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 93 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 94 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 95 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 96 NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 97 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 98 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 99 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 100 US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 101 US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 102 US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 103 US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 104 US: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 105 US: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 106 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 107 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 108 CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 109 CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 110 CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 111 CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 112 CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 113 CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 114 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 115 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 116 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 117 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 118 EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 119 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 120 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 121 EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 122 EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 123 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 124 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 125 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 126 GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 127 GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 128 GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 129 GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 130 GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 131 GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 132 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 133 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 134 FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 135 FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 136 FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 137 FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 138 FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 139 FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 140 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 141 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 142 UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 143 UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 144 UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 145 UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 146 UK: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 147 UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 148 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 149 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 150 ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 151 ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 152 ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 153 ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 154 ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 155 ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 156 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 157 SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 158 SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 159 SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 160 SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 161 SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 162 SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 163 SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 164 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 165 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 166 SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 167 SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 168 SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 169 SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 170 SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 171 SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 172 REST OF EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 173 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 174 REST OF EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 175 REST OF EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 176 REST OF EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 177 REST OF EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 178 REST OF EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 179 REST OF EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 180 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 181 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 182 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 183 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 184 ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 185 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 186 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 187 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 188 ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 189 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 190 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 191 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 192 CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 193 CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 194 CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 195 CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 196 CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 197 CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 198 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 199 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 200 JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 201 JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 202 JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 203 JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 204 JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 205 JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 206 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 207 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 208 INDIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 209 INDIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 210 INDIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 211 INDIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 212 INDIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 213 INDIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 214 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 215 AUSTRALIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 216 AUSTRALIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 217 AUSTRALIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 218 AUSTRALIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 219 AUSTRALIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 220 AUSTRALIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 221 AUSTRALIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 222 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 223 SOUTH KOREA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 224 SOUTH KOREA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 225 SOUTH KOREA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 226 SOUTH KOREA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 227 SOUTH KOREA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 228 SOUTH KOREA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 229 SOUTH KOREA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 230 REST OF ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 231 REST OF ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 232 REST OF ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 233 REST OF ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 234 REST OF ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 235 REST OF ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 236 REST OF ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 237 REST OF ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 238 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 239 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 240 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 241 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 242 LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 243 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 244 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 245 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 246 LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 247 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 248 BRAZIL: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 249 BRAZIL: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 250 BRAZIL: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 251 BRAZIL: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 252 BRAZIL: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 253 BRAZIL: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 254 BRAZIL: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 255 BRAZIL: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 256 MEXICO: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 257 MEXICO: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 258 MEXICO: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 259 MEXICO: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 260 MEXICO: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 261 MEXICO: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 262 MEXICO: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 263 MEXICO: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 264 REST OF LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 265 REST OF LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 266 REST OF LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 267 REST OF LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 268 REST OF LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 269 REST OF LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 270 REST OF LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 271 REST OF LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 272 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 273 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 274 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 275 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 276 MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 277 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 278 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 279 MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 280 MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 281 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 282 GCC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 283 GCC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 284 GCC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 285 GCC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 286 GCC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 287 GCC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 288 GCC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 289 GCC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 290 REST OF MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 291 REST OF MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 292 REST OF MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 293 REST OF MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 294 REST OF MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 295 REST OF MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 296 REST OF MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 297 REST OF MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) TABLE 298 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEGREE OF COMPETITION TABLE 299 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SERVICE FOOTPRINT TABLE 300 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: END-USER FOOTPRINT TABLE 301 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: REGIONAL FOOTPRINT TABLE 302 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DETAILED LIST OF KEY START-UPS/SMES TABLE 303 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES TABLE 304 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2020-MARCH 2024 TABLE 305 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEALS, JANUARY 2020-MARCH 2024 TABLE 306 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: EXPANSIONS, JANUARY 2020-MARCH 2024 TABLE 307 EUROFINS SCIENTIFIC: COMPANY OVERVIEW TABLE 308 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 309 EUROFINS SCIENTIFIC: DEALS TABLE 310 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW TABLE 311 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 312 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS TABLE 313 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS TABLE 314 WUXI APPTEC: COMPANY OVERVIEW TABLE 315 WUXI APPTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 316 WUXI APPTEC: SERVICE LAUNCHES TABLE 317 WUXI APPTEC: DEALS TABLE 318 WUXI APPTEC: EXPANSIONS TABLE 319 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW TABLE 320 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 321 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES TABLE 322 CHARLES RIVER LABORATORIES: DEALS TABLE 323 SGS S.A.: COMPANY OVERVIEW TABLE 324 SGS S.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 325 SGS S.A.: DEALS TABLE 326 SGS S.A.: OTHER DEVELOPMENTS TABLE 327 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW TABLE 328 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 329 THERMO FISHER SCIENTIFIC INC.: DEALS TABLE 330 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS TABLE 331 MEDPACE, INC.: COMPANY OVERVIEW TABLE 332 MEDPACE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 333 SARTORIUS AG: COMPANY OVERVIEW TABLE 334 SARTORIUS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 335 SARTORIUS AG: DEALS TABLE 336 INTERTEK GROUP PLC: COMPANY OVERVIEW TABLE 337 INTERTEK GROUP PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 338 INTERTEK GROUP PLC: DEALS TABLE 339 INTERTEK GROUP PLC: EXPANSIONS TABLE 340 MERCK KGAA: COMPANY OVERVIEW TABLE 341 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 342 MERCK KGAA: SERVICE LAUNCHES TABLE 343 MERCK KGAA: DEALS TABLE 344 MERCK KGAA: EXPANSIONS TABLE 345 MERCK KGAA: OTHER DEVELOPMENTS TABLE 346 SOURCE BIOSCIENCE: COMPANY OVERVIEW TABLE 347 SOURCE BIOSCIENCE: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 348 SOURCE BIOSCIENCE: SERVICE LAUNCHES TABLE 349 SOURCE BIOSCIENCE: EXPANSIONS TABLE 350 ICON PLC: COMPANY OVERVIEW TABLE 351 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 352 ICON PLC: DEALS TABLE 353 ALS: COMPANY OVERVIEW TABLE 354 ALS: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 355 ALS: DEALS TABLE 356 FRONTAGE LABORATORIES, INC.: COMPANY OVERVIEW TABLE 357 FRONTAGE LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 358 FRONTAGE LABORATORIES, INC.: DEALS TABLE 359 FRONTAGE LABORATORIES, INC.: OTHER DEVELOPMENTS TABLE 360 STERIS: COMPANY OVERVIEW TABLE 361 STERIS: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 362 IQVIA INC.: COMPANY OVERVIEW TABLE 363 IQVIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 364 IQVIA INC.: OTHER DEVELOPMENTS TABLE 365 ELEMENT MATERIALS TECHNOLOGY: COMPANY OVERVIEW TABLE 366 ELEMENT MATERIALS TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 367 ELEMENT MATERIALS TECHNOLOGY: SERVICE LAUNCHES TABLE 368 ELEMENT MATERIALS TECHNOLOGY: DEALS TABLE 369 ELEMENT MATERIALS TECHNOLOGY: EXPANSIONS TABLE 370 PACE ANALYTICAL SERVICES: COMPANY OVERVIEW TABLE 371 PACE ANALYTICAL SERVICES: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 372 PACE ANALYTICAL SERVICES: DEALS TABLE 373 PACE ANALYTICAL SERVICES: OTHER DEVELOPMENTS TABLE 374 ALMAC GROUP: COMPANY OVERVIEW TABLE 375 ALMAC GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 376 ALMAC GROUP: SERVICE LAUNCHES TABLE 377 ALMAC GROUP: EXPANSIONS TABLE 378 PHARMARON: COMPANY OVERVIEW TABLE 379 PHARMARON: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 380 PHARMARON: DEALS TABLE 381 SYNEOS HEALTH: COMPANY OVERVIEW TABLE 382 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW TABLE 383 LGC LIMITED: COMPANY OVERVIEW TABLE 384 CELERION: COMPANY OVERVIEW TABLE 385 BIOAGILYTIX: COMPANY OVERVIEW
FIGURE 1 MARKETS COVERED FIGURE 2 REGIONAL SEGMENTATION FIGURE 3 RESEARCH DESIGN FIGURE 4 PRIMARY SOURCES FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS FIGURE 8 REVENUE SHARE ANALYSIS: COMPANY ILLUSTRATION FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION FIGURE 10 TOP-DOWN APPROACH FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FIGURE 12 CAGR PROJECTIONS FIGURE 13 DATA TRIANGULATION METHODOLOGY FIGURE 14 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) FIGURE 15 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) FIGURE 16 PHYSICAL CHARACTERIZATION TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) FIGURE 17 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) FIGURE 18 GEOGRAPHICAL SNAPSHOT OF HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FIGURE 19 GROWING ADOPTION OF OUTSOURCED ANALYTICAL TESTING SERVICES BY PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES TO DRIVE GROWTH FIGURE 20 BIOANALYTICAL TESTING SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2023 FIGURE 21 CHINA, INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD FIGURE 22 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD (2022-2029) FIGURE 23 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD FIGURE 24 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2004-2024) FIGURE 26 PERCENTAGE OF REGISTERED STUDIES BY LOCATION (AS OF MARCH 08, 2024) FIGURE 27 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2002-2022 FIGURE 28 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ECOSYSTEM ANALYSIS FIGURE 29 VALUE CHAIN ANALYSIS FIGURE 30 PORTER’S FIVE FORCES ANALYSIS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FIGURE 31 REVENUE SHIFT AND NEW POCKETS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FIGURE 32 NUMBER OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018-2022 FIGURE 33 VALUE OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018-2022 FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FIGURE 35 KEY BUYING CRITERIA FOR END USERS FIGURE 36 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2020-2022 FIGURE 37 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC SNAPSHOT FIGURE 38 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FIGURE 39 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2021) FIGURE 40 CANADA: ONGOING CLINICAL TRIALS, BY THERAPEUTIC AREA (2023) FIGURE 41 ASIA PACIFIC: HEALTHCARE ANALYTICS TESTING SERVICES MARKET SNAPSHOT FIGURE 42 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: STRATEGIES ADOPTED FIGURE 43 REVENUE ANALYSIS FOR KEY PLAYERS (2018-2022) FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) FIGURE 45 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 FIGURE 46 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: OVERALL FOOTPRINT FIGURE 47 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023 FIGURE 48 EV/EBITDA OF KEY VENDORS FIGURE 49 BRAND/PRODUCT COMPARATIVE ANALYSIS OF KEY PLAYERS, BY SERVICE TYPE FIGURE 50 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) FIGURE 51 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022) FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT (2022) FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022) FIGURE 54 SGS S.A.: COMPANY SNAPSHOT (2023) FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) FIGURE 56 MEDPACE, INC.: COMPANY SNAPSHOT (2022) FIGURE 57 SARTORIUS AG: COMPANY SNAPSHOT (2022) FIGURE 58 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2022) FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT (2022) FIGURE 60 SOURCE BIOSCIENCE: COMPANY SNAPSHOT (2022) FIGURE 61 ICON PLC: COMPANY SNAPSHOT (2022) FIGURE 62 ALS: COMPANY SNAPSHOT (2022) FIGURE 63 FRONTAGE LABORATORIES, INC.: COMPANY SNAPSHOT (2022) FIGURE 64 STERIS: COMPANY SNAPSHOT (2023) FIGURE 65 IQVIA INC.: COMPANY SNAPSHOT (2023)
